ZMB Member Dirk Schadendorf
ZMB Member
Dirk Schadendorf
Next ZMB-Member
Prof. Dr. Dirk Schadendorf
Director of:
Clinic for Dermatology
University Hospital Essen
Hufelandstraße 55
45147 Essen
- +49 201 723 4342
- Website
- Selected Publications
- Publication Metrics
- ZMB Research Program
Oncology
Research Overview
- Malignant melanoma
- Merkel cell carcinoma
- Squamous cell carcinoma
- Basal cell carcinoma
- Mycosis Fungoides/Sezary syndrome (T-Zell-Non-Hodgkin-Lymphoma)
- Application observation
Selected Publications
-
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054) : Long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trialIn: The Lancet Oncology Vol. 25 (2024) Nr. 9, pp. 1202 - 1212Online Full Text: dx.doi.org/
-
Analyses of non-coding somatic drivers in 2,658 cancer whole genomesIn: Nature Vol. 578 (2023) Nr. 7793, pp. 102 - 111Online Full Text: dx.doi.org/
-
Author Correction : Genomic basis for RNA alterations in cancerIn: Nature Vol. 614 (2023) Nr. 7948, pp. E37Online Full Text: dx.doi.org/
-
Author Correction : Patterns of somatic structural variation in human cancer genomesIn: Nature Vol. 614 (2023) Nr. 7948, pp. E38Online Full Text: dx.doi.org/ (Open Access)
-
Author Correction : The evolutionary history of 2,658 cancersIn: Nature Vol. 614 (2023) pp. E42Online Full Text: dx.doi.org/
-
Author Correction: : The repertoire of mutational signatures in human cancerIn: Nature Vol. 614 (2023) pp. E41Online Full Text: dx.doi.org/ (Open Access)
-
Author Correction: Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencingIn: Nature Genetics Vol. 55 (2023) Nr. 6, 1076Online Full Text: dx.doi.org/ (Open Access)
-
Author Correction: Comprehensive molecular characterization of mitochondrial genomes in human cancersIn: Nature Genetics Vol. 55 (2023) Nr. 6, pp. 1078Online Full Text: dx.doi.org/ (Open Access)
-
Author Correction: Disruption of chromatin folding domains by somatic genomic rearrangements in human cancerIn: Nature Genetics Vol. 55 (2023) Nr. 6, pp. 1079Online Full Text: dx.doi.org/ (Open Access)
-
Author Correction: Pan-cancer analysis of whole genomesIn: Nature Vol. 614 (2023) Nr. 7948, pp. E39Online Full Text: dx.doi.org/ (Open Access)
-
Author Correction: Pan-cancer analysis of whole genomes identifies driver rearrangements promoted by LINE-1 retrotranspositionIn: Nature Genetics Vol. 55 (2023) Nr. 6, 1080Online Full Text: dx.doi.org/ (Open Access)
-
Author Correction: The landscape of viral associations in human cancersIn: Nature Genetics Vol. 55 (2023) Nr. 6, pp. 1077Online Full Text: dx.doi.org/ (Open Access)
-
Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencingIn: Nature Genetics Vol. 52 (2023) pp. 331 - 341Online Full Text: dx.doi.org/ (Open Access)
-
Comprehensive molecular characterization of mitochondrial genomes in human cancersIn: Nature Genetics Vol. 52 (2023) pp. 342 - 352Online Full Text: dx.doi.org/ (Open Access)
-
Disruption of chromatin folding domains by somatic genomic rearrangements in human cancerIn: Nature Genetics Vol. 52 (2023) Nr. 3, pp. 294 - 305Online Full Text: dx.doi.org/ (Open Access)
-
Genomic basis for RNA alterations in cancerIn: Nature Vol. 578 (2023) Nr. 7793, pp. 129 - 136Online Full Text: dx.doi.org/
-
Neoadjuvant cemiplimab and surgery for stage II–IV cutaneous squamous-cell carcinoma : follow-up and survival outcomes of a single-arm, multicentre, phase 2 studyIn: The Lancet Oncology Vol. 24 (2023) Nr. 11, pp. 1196 - 1205Online Full Text: dx.doi.org/
-
Neoadjuvant immunotherapy for melanoma is now ready for clinical practiceIn: Nature Medicine Vol. 29 (2023) Nr. 6, pp. 1310 - 1312Online Full Text: dx.doi.org/
-
Pan-cancer analysis of whole genomes identifies driver rearrangements promoted by LINE-1 retrotranspositionIn: Nature Genetics Vol. 52 (2023) Nr. 3, pp. 306 - 319Online Full Text: dx.doi.org/ (Open Access)
-
Patterns of somatic structural variation in human cancer genomesIn: Nature Vol. 578 (2023) Nr. 7793, pp. 112 - 121Online Full Text: dx.doi.org/
-
The German Network for Personalized Medicine to enhance patient care and translational researchIn: Nature Medicine Vol. 29 (2023) Nr. 6, pp. 1298 - 1301Online Full Text: dx.doi.org/
-
The landscape of viral associations in human cancersIn: Nature Genetics (2023) Nr. 52, pp. 320 - 330Online Full Text: dx.doi.org/ (Open Access)
-
The repertoire of mutational signatures in human cancerIn: Nature Vol. 578 (2023) Nr. 7793, pp. 94 - 101Online Full Text: dx.doi.org/ (Open Access)
-
Author Correction : Pathway and network analysis of more than 2500 whole cancer genomesIn: Nature Communications Vol. 13 (2022) 7566Online Full Text: dx.doi.org/ (Open Access)
-
Author Correction : Genomic footprints of activated telomere maintenance mechanisms in cancerIn: Nature Communications Vol. 13 (2022) 7574Online Full Text: dx.doi.org/ (Open Access)
-
Author Correction : Combined burden and functional impact tests for cancer driver discovery using DriverPowerIn: Nature Communications Vol. 13 (2022) 7571Online Full Text: dx.doi.org/ (Open Access)
-
Author Correction : Inferring structural variant cancer cell fractionIn: Nature Communications Vol. 13 (2022) 7568Online Full Text: dx.doi.org/ (Open Access)
-
Author Correction : Reconstructing evolutionary trajectories of mutation signature activities in cancer using TrackSigIn: Nature Communications Vol. 13 (2022) 7567Online Full Text: dx.doi.org/ (Open Access)
-
Author Correction : A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patternsIn: Nature Communications Vol. 13 (2022) 7573Online Full Text: dx.doi.org/ (Open Access)
-
Author Correction : Integrative pathway enrichment analysis of multivariate omics dataIn: Nature Communications Vol. 13 (2022) 7570Online Full Text: dx.doi.org/ (Open Access)
-
Author Correction : Divergent mutational processes distinguish hypoxic and normoxic tumoursIn: Nature Communications Vol. 13 (2022) 7569Online Full Text: dx.doi.org/ (Open Access)
-
Author Correction : High-coverage whole-genome analysis of 1220 cancers reveals hundreds of genes deregulated by rearrangement-mediated cis-regulatory alterationsIn: Nature Communications Vol. 13 (2022) 7572Online Full Text: dx.doi.org/ (Open Access)
-
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716) : distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trialIn: The Lancet Oncology Vol. 23 (2022) Nr. 11, pp. 1378 - 1388Online Full Text: dx.doi.org/
-
Persister state-directed transitioning and vulnerability in melanomaIn: Nature Communications Vol. 13 (2022) Nr. 1, 3055Online Full Text: dx.doi.org/ Online Full Text (Open Access)
-
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054) : health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trialIn: The Lancet Oncology Vol. 22 (2021) Nr. 5, pp. 655 - 664Online Full Text: dx.doi.org/ Online Full Text (Open Access)
-
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054) : distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trialIn: The Lancet Oncology Vol. 22 (2021) Nr. 5, pp. 643 - 654Online Full Text: dx.doi.org/
-
Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib : A clinical validation studyIn: The Lancet Oncology Vol. 22 (2021) Nr. 3, pp. 370 - 380Online Full Text: dx.doi.org/ Online Full Text (Open Access)
-
EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumoursIn: Annals of Oncology Vol. 32 (2021) Nr. 11, pp. 1332 - 1347Online Full Text: dx.doi.org/ (Open Access)
-
Multimodal pooled Perturb-CITE-seq screens in patient models define mechanisms of cancer immune evasionIn: Nature Genetics Vol. 53 (2021) Nr. 3, pp. 332 - 341Online Full Text: dx.doi.org/; Online Full Text: dx.doi.org/ (Open Access)
-
A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patternsIn: Nature Communications Vol. 11 (2020) 728Online Full Text: dx.doi.org/ (Open Access)
-
Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV⁶⁰⁰-mutant, stage III melanoma (COMBI-AD) : Exploratory biomarker analyses from a randomised, phase 3 trialIn: The Lancet Oncology Vol. 21 (2020) Nr. 3, pp. 358 - 372Online Full Text: dx.doi.org/ Online Full Text (Open Access)
-
Association between Immune-Related Adverse Events and Recurrence-Free Survival among Patients with Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo : A Secondary Analysis of a Randomized Clinical TrialIn: JAMA Oncology Vol. 6 (2020) Nr. 4, pp. 519 - 527Online Full Text: dx.doi.org/ (Open Access)
-
Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition with Pembrolizumab Outcomes in Advanced Melanoma : Pooled Analysis of 3 Clinical TrialsIn: JAMA Oncology Vol. 6 (2020) Nr. 8, pp. 1256 - 1264Online Full Text: dx.doi.org/ (Open Access)
-
Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanomaIn: Nature Medicine Vol. 26 (2020) Nr. 7, pp. 1147Online Full Text: dx.doi.org/ (Open Access)
-
Author Correction: Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samplesIn: Nature Communications Vol. 11 (2020) Nr. 1, pp. 6232Online Full Text: dx.doi.org/ (Open Access)
-
Author Correction: Tertiary lymphoid structures improve immunotherapy and survival in melanomaIn: Nature Vol. 580 (2020) Nr. 7801, pp. E1Online Full Text: dx.doi.org/ (Open Access)
-
Cancer immune control needs senescence induction by interferon-dependent cell cycle regulator pathways in tumoursIn: Nature Communications Vol. 11 (2020) Nr. 1, pp. 1335Online Full Text: dx.doi.org/ (Open Access)
-
Cemiplimab in locally advanced cutaneous squamous cell carcinoma : results from an open-label, phase 2, single-arm trialIn: The Lancet Oncology Vol. 21 (2020) Nr. 2, pp. 294 - 305Online Full Text: dx.doi.org/ Online Full Text (Open Access)
-
Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma : safety run-in and biomarker cohorts of COMBI-iIn: Nature Medicine Vol. 26 (2020) Nr. 10, pp. 1557 - 1563Online Full Text: dx.doi.org/
-
Combined burden and functional impact tests for cancer driver discovery using DriverPowerIn: Nature Communications Vol. 11 (2020) 734Online Full Text: dx.doi.org/ (Open Access)
-
Divergent mutational processes distinguish hypoxic and normoxic tumoursIn: Nature Communications Vol. 11 (2020) 737Online Full Text: dx.doi.org/ (Open Access)
-
Elevated baseline serum PD-1 or PD-L1 predicts poor outcome of PD-1 inhibition therapy in metastatic melanomaIn: Annals of Oncology Vol. 31 (2020) Nr. 1, pp. 144 - 152Online Full Text: dx.doi.org/ (Open Access)
-
Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibilityIn: Nature Genetics Vol. 52 (2020) Nr. 5, pp. 494 - 504Online Full Text: dx.doi.org/ Online Full Text (Open Access)
-
Genomic footprints of activated telomere maintenance mechanisms in cancerIn: Nature Communications Vol. 11 (2020) 733Online Full Text: dx.doi.org/ (Open Access)
-
High-coverage whole-genome analysis of 1220 cancers reveals hundreds of genes deregulated by rearrangement-mediated cis-regulatory alterationsIn: Nature Communications Vol. 11 (2020) 736Online Full Text: dx.doi.org/ (Open Access)
-
Inferring structural variant cancer cell fractionIn: Nature Communications Vol. 11 (2020) 730Online Full Text: dx.doi.org/ (Open Access)
-
Integrated molecular drivers coordinate biological and clinical states in melanomaIn: Nature Genetics Vol. 52 (2020) Nr. 12, pp. 1373 - 1383Online Full Text: dx.doi.org/ Online Full Text (Open Access)
-
Integrative pathway enrichment analysis of multivariate omics dataIn: Nature Communications Vol. 11 (2020) 735Online Full Text: dx.doi.org/ (Open Access)
-
Metabolic heterogeneity confers differences in melanoma metastatic potentialIn: Nature Vol. 577 (2020) Nr. 7788, pp. 115 - 120Online Full Text: dx.doi.org/ Online Full Text (Open Access)
-
Pan-cancer analysis of whole genomesIn: Nature Vol. 578 (2020) Nr. 7793, pp. 82 - 93Online Full Text: dx.doi.org/ (Open Access)
-
Pathway and network analysis of more than 2500 whole cancer genomesIn: Nature Communications Vol. 11 (2020) 729Online Full Text: dx.doi.org/ (Open Access)
-
Prognostic impact of baseline tumour immune infiltrate on disease-free survival in patients with completely resected, BRAFv⁶⁰⁰ mutation–positive melanoma receiving adjuvant vemurafenibIn: Annals of Oncology Vol. 31 (2020) Nr. 1, pp. 153 - 159Online Full Text: dx.doi.org/ (Open Access)
-
Rationale for Immune Checkpoint Inhibitors plus Targeted Therapy in Metastatic Melanoma : A ReviewIn: JAMA Oncology Vol. 6 (2020) Nr. 12, pp. 1957 - 1966Online Full Text: dx.doi.org/
-
Reconstructing evolutionary trajectories of mutation signature activities in cancer using TrackSigIn: Nature Communications Vol. 11 (2020) 731Online Full Text: dx.doi.org/ (Open Access)
-
Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samplesIn: Nature Communications Vol. 11 (2020) Nr. 1, pp. 4748Online Full Text: dx.doi.org/ (Open Access)
-
Sex differences in oncogenic mutational processesIn: Nature Communications Vol. 11 (2020) Nr. 1, pp. 4330Online Full Text: dx.doi.org/ (Open Access)
-
Tertiary lymphoid structures improve immunotherapy and survival in melanomaIn: Nature Vol. 577 (2020) Nr. 7791, pp. 561 - 565Online Full Text: dx.doi.org/
-
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanomaIn: Nature Medicine Vol. 25 (2019) Nr. 12, pp. 1916 - 1927Online Full Text: dx.doi.org/ (Open Access)
-
Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL) : a multicentre, open-label, randomised, controlled phase II trialIn: Annals of Oncology Vol. 30 (2019) Nr. 2, pp. 317 - 324Online Full Text: dx.doi.org/ (Open Access)
-
Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD) : a randomised, placebo-controlled, phase 3 trialIn: The Lancet Oncology Vol. 20 (2019) Nr. 5, pp. 701 - 710Online Full Text: dx.doi.org/
-
Publisher Correction : Novel pleiotropic risk loci for melanoma and nevus density implicate multiple biological pathwaysIn: Nature Communications Vol. 10 (2019) Nr. 1, pp. 299Online Full Text: dx.doi.org/ (Open Access)
-
Publisher Correction: Novel pleiotropic risk loci for melanoma and nevus density implicate multiple biological pathwaysIn: Nature Communications Vol. 10 (2019) Nr. 1, pp. 299Online Full Text: dx.doi.org/ (Open Access)
-
Survival Outcomes in Patients with Previously Untreated BRAF Wild-Type Advanced Melanoma Treated with Nivolumab Therapy : Three-Year Follow-up of a Randomized Phase 3 TrialIn: JAMA Oncology Vol. 5 (2019) Nr. 2, pp. 187 - 194Online Full Text: dx.doi.org/ (Open Access)
-
Treatment in metastatic melanoma : Time to re-thinkIn: Annals of Oncology Vol. 30 (2019) Nr. 4, pp. 501 - 503Online Full Text: dx.doi.org/ (Open Access)
-
A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint BlockadeIn: Cell Vol. 175 (2018) Nr. 4, pp. 984 - 997.e24Online Full Text: dx.doi.org/ (Open Access)
-
Adjuvant melanoma therapy with new drugs : Should physicians continue to focus on metastatic disease or use it earlier in primary melanoma?In: The Lancet Oncology Vol. 19 (2018) Nr. 12, pp. e720 - e725Online Full Text: dx.doi.org/
-
Adjuvant vemurafenib in resected, BRAF mutation-positive melanoma (BRIM8) : a randomised, double-blind, placebo-controlled, multicentre, phase 3 trialIn: The Lancet Oncology Vol. 19 (2018) Nr. 4, pp. 510 - 520Online Full Text: dx.doi.org/
-
Adverse events (AEs) over time in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (Pbo) in the COMBI-AD trialIn: Annals of Oncology Vol. 29 (2018) Nr. Suppl. 8, pp. viii446Online Full Text: dx.doi.org/ (Open Access)
-
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy : a retrospective, multicohort analysisIn: The Lancet Oncology Vol. 19 (2018) Nr. 3, pp. 310 - 322Online Full Text: dx.doi.org/ Online Full Text (Open Access)
-
Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 BlockadeIn: Cell Vol. 173 (2018) Nr. 3, pp. 624 - 633.e8Online Full Text: dx.doi.org/ Online Full Text (Open Access)
-
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS) : a multicentre, open-label, randomised phase 3 trialIn: The Lancet Oncology Vol. 19 (2018) Nr. 5, pp. 603 - 615Online Full Text: dx.doi.org/; Online Full Text: dx.doi.org/ (Open Access)
-
Estimate of long-term relapse-free survival (RFS) and analysis of baseline factors associated with RFS in the COMBI-AD trialIn: Annals of Oncology Vol. 29 (2018) Nr. Suppl. 8, pp. viii445Online Full Text: dx.doi.org/ (Open Access)
-
Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumorsIn: Nature Genetics Vol. 50 (2018) Nr. 9, pp. 1271 - 1281Online Full Text: dx.doi.org/ Online Full Text (Open Access)
-
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067) : 4-year outcomes of a multicentre, randomised, phase 3 trialIn: The Lancet Oncology Vol. 19 (2018) Nr. 11, pp. 1480 - 1492Online Full Text: dx.doi.org/
-
Novel pleiotropic risk loci for melanoma and nevus density implicate multiple biological pathwaysIn: Nature Communications Vol. 9 (2018) Nr. 1, pp. 4774Online Full Text: dx.doi.org/ (Open Access)
-
Overall survival at 4 years of follow-up in a phase III trial of nivolumab plus ipilimumab combination therapy in advanced melanoma (CheckMate 067)In: Annals of Oncology Vol. 29 (2018) Nr. Suppl. 8, pp. viii735Online Full Text: dx.doi.org/ (Open Access)
-
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS) : A multicentre, open-label, randomised, phase 3 trialIn: The Lancet Oncology Vol. 19 (2018) Nr. 10, pp. 1315 - 1327Online Full Text: dx.doi.org/
-
Sebaceous tumours: more than skin deepIn: Gut Vol. 67 (2018) Nr. 11, pp. 2045 - 2053Online Full Text: dx.doi.org/
-
Updated relapse-free survival (RFS) and biomarker analysis in the COMBI-AD trial of adjuvant dabrafenib + trametinib (D + T) in patients (pts) with resected BRAF V600-mutant stage III melanomaIn: Annals of Oncology Vol. 29 (2018) Nr. Suppl. 8, pp. viii734 - viii735Online Full Text: dx.doi.org/ (Open Access)
-
Updated relapse-free survival (RFS) and biomarker analysis in the COMBI-AD trial of adjuvant dabrafenib plus trametinib (D plus T) in patients (pts) with resected BRAF V600-mutant stage III melanomaIn: Annals of Oncology Vol. 29 (2018) Nr. Suppl. 8,
-
Acquired IFNγ 3 resistance impairs anti-Tumor immunity and gives rise to T-cell-resistant melanoma lesionsIn: Nature Communications Vol. 8 (2017) 15440Online Full Text: dx.doi.org/ (Open Access)
-
Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO) : a multicentre, open-label, randomised, phase 3 trialIn: The Lancet Oncology Vol. 18 (2017) Nr. 4, pp. 435 - 445Online Full Text: dx.doi.org/
-
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma : long-term survival and safety analysis of a phase 3 studyIn: Annals of Oncology Vol. 28 (2017) Nr. 7, pp. 1631 - 1639Online Full Text: dx.doi.org/ (Open Access)
-
Efficacy and safety of nilotinib in patients with kit-mutated metastatic or inoperable melanoma : Final results from the global, single-arm, phase ii team trialIn: Annals of Oncology Vol. 28 (2017) Nr. 6, pp. 1380 - 1387Online Full Text: dx.doi.org/ (Open Access)
-
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma : a randomised, double-blind, multicentre, phase 3 trialIn: The Lancet Oncology Vol. 18 (2017) Nr. 5, pp. 611 - 622Online Full Text: dx.doi.org/
-
Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression : Analysis of 2 Phase 3 Clinical TrialsIn: JAMA Oncology Vol. 3 (2017) Nr. 11, pp. 1511 - 1519Online Full Text: dx.doi.org/ Online Full Text (Open Access)
-
Predictors of responses to immune checkpoint blockade in advanced melanomaIn: Nature Communications Vol. 8 (2017) pp. 592Online Full Text: dx.doi.org/ (Open Access)
-
Spatiotemporally restricted arenavirus replication induces immune surveillance and type i interferon-dependent tumour regressionIn: Nature Communications Vol. 8 (2017) pp. 14447Online Full Text: dx.doi.org/ (Open Access)
-
Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE) : a randomised, regimen-controlled, double-blind, phase 2 trialIn: The Lancet Oncology Vol. 18 (2017) Nr. 3, pp. 404 - 412Online Full Text: dx.doi.org/
-
Vemurafenib in metastatic melanoma patients with brain metastases : An open-label, single-arm, phase 2, multicentre studyIn: Annals of Oncology Vol. 28 (2017) Nr. 3, pp. 634 - 641Online Full Text: dx.doi.org/
-
A phase I, open-label study of pasireotide in patients with BRAF- and NRAS-wild type, unresectable and or metastatic melanomaIn: Annals of Oncology Vol. 27 (2016) Nr. Suppl. 6,Online Full Text: dx.doi.org/
-
Adjuvant treatment with pegylated interferon ?-2a versus low-dose interferon ?-2a in patients with high-risk melanoma : a randomized phase III DeCOG trialIn: Annals of Oncology Vol. 27 (2016) Nr. 8, pp. 1625 - 1632Online Full Text: dx.doi.org/ (Open Access)
-
Analysis of BRAF V600E mutation status – concordance of results from circulating tumor DNA and tissue-based testing and impact on prediction of the clinical course in patients undergoing BRAFi therapyIn: Annals of Oncology Vol. 27 (2016) Nr. Suppl. 6, pp. 1145POnline Full Text: dx.doi.org/
-
Analysis of patient-reported outcomes by disease progression status in patients (pts) with BRAF V600–mutant metastatic melanoma in the COMBI-d and COMBI-v trialsIn: Annals of Oncology Vol. 27 (2016) Nr. Suppl. 6, pp. 1140POnline Full Text: dx.doi.org/
-
Checkpoint inhibitors : a new standard of care for advanced Merkel cell carcinoma?In: The Lancet Oncology Vol. 17 (2016) Nr. 10, pp. 1337 - 1339Online Full Text: dx.doi.org/
-
Evaluation of the pharmacokinetic (PK) profile of vismodegib (VISMO) in patients (pts) with multiple basal cell carcinomas (BCCs) across two intermittent treatment regimens in the MIKIE studyIn: Annals of Oncology Vol. 27 (2016) Nr. Suppl. 6, pp. 1152POnline Full Text: dx.doi.org/
-
Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment : a pooled analysis of individual patient data from randomised trialsIn: The Lancet Oncology Vol. 17 (2016) Nr. 12, pp. 1743 - 1754Online Full Text: dx.doi.org/
-
Final overall survival for KEYNOTE-002 : pembrolizumab (pembro) versus investigator-choice chemotherapy (chemo) for ipilimumab (ipi)-refractory melanomaIn: Annals of Oncology Vol. 27 (2016) Nr. Suppl. 6, pp. 1107OOnline Full Text: dx.doi.org/
-
Health-related quality-of-life (HRQOL) impact of dabrafenib (D) and trametinib (T) vs BRAF inhibitor (BRAFi) monotherapy by lactate dehydrogenase (LDH) in patients (pts) with BRAF V600–mutant melanomaIn: Annals of Oncology Vol. 27 (2016) Nr. Suppl. 6, pp. 1137POnline Full Text: dx.doi.org/
-
PD-L1 expression as a biomarker for nivolumab (NIVO) plus ipilimumab (IPI) and NIVO alone in advanced melanoma (MEL) : A pooled analysisIn: Annals of Oncology Vol. 27 (2016) Nr. Suppl. 6, pp. 1112PDOnline Full Text: dx.doi.org/
-
Pooled analysis of factors to predict durable clinical outcomes with combination dabrafenib (D) and trametinib (T) across registration trialsIn: Annals of Oncology Vol. 27 (2016) Nr. Suppl. 6, pp. 1134POnline Full Text: dx.doi.org/
-
Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study evaluating first-line dabrafenib (D) + trametinib (T) in patients (pts) with unresectable or metastatic BRAF V600E/K–mutant cutaneous melanomaIn: Annals of Oncology Vol. 27 (2016) Nr. Suppl. 6, pp. LBA40Online Full Text: dx.doi.org/
-
sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistanceIn: Nature Vol. 532 (2016) Nr. 7598, pp. 250 - 254Online Full Text: dx.doi.org/ Online Full Text (Open Access)
-
A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma : pretreatment impacts survivalIn: Annals of Oncology Vol. 26 (2015) Nr. 3, pp. 573 - 582Online Full Text: dx.doi.org/ (Open Access)
-
Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v) : results of a phase 3, open-label, randomised trialIn: The Lancet Oncology Vol. 16 (2015) Nr. 13, pp. 1389 - 1398Online Full Text: dx.doi.org/
-
Disease kinetics for decision-making in advanced melanoma : a call for scenario-driven strategy trialsIn: The Lancet Oncology Vol. 16 (2015) Nr. 13, pp. e522 - e526Online Full Text: dx.doi.org/
-
Expanded access programmes : patient interests versus clinical trial integrityIn: The Lancet Oncology Vol. 16 (2015) Nr. 1, pp. 15 - 17Online Full Text: dx.doi.org/
-
Genome-wide meta-analysis identifies five new susceptibility loci for cutaneous malignant melanomaIn: Nature Genetics Vol. 47 (2015) Nr. 9, pp. 987 - 995Online Full Text: dx.doi.org/ Online Full Text (Open Access)
-
Genomic Classification of Cutaneous MelanomaIn: Cell Vol. 161 (2015) Nr. 7, pp. 1681 - 1696Online Full Text: dx.doi.org/ (Open Access)
-
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002) : a randomised, controlled, phase 2 trialIn: The Lancet Oncology Vol. 16 (2015) Nr. 8, pp. 908 - 918Online Full Text: dx.doi.org/
-
Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patientsIn: Annals of Oncology Vol. 26 (2015) Nr. 6, pp. 1238 - 1244Online Full Text: dx.doi.org/ (Open Access)
-
Reply to the letters to the editor ‘Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma’ by Diwakar et al.In: Annals of Oncology Vol. 26 (2015) Nr. 1, pp. 250 - 251Online Full Text: dx.doi.org/
-
Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanomaIn: Annals of Oncology Vol. 25 (2014) Nr. 3, pp. 747 - 753Online Full Text: dx.doi.org/
-
Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma : Quality-of-life analyses of the METRIC studyIn: Annals of Oncology Vol. 25 (2014) Nr. 3, pp. 700 - 706Online Full Text: dx.doi.org/
-
Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021) : A multicentric randomized trialIn: Annals of Oncology Vol. 25 (2014) Nr. 3, pp. 742 - 746Online Full Text: dx.doi.org/
-
Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3) : extended follow-up of a phase 3, randomised, open-label studyIn: The Lancet Oncology Vol. 15 (2014) Nr. 3, pp. 323 - 332Online Full Text: dx.doi.org/ Online Full Text (Open Access)
-
Surrogate endpoints for overall survival in metastatic melanoma: A meta-analysis of randomised controlled trialsIn: The Lancet Oncology Vol. 15 (2014) Nr. 3, pp. 297 - 304Online Full Text: dx.doi.org/
-
Ultraviolet-radiation-induced inflammation promotes angiotropism and metastasis in melanomaIn: Nature Vol. 507 (2014) Nr. 7490, pp. 109 - 113Online Full Text: dx.doi.org/
-
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: A non-randomised, open-label phase 2 studyIn: The Lancet Oncology Vol. 14 (2013) Nr. 3, pp. 249 - 256Online Full Text: dx.doi.org/
-
Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma : A phase 2 double-blind randomised studyIn: The Lancet Oncology Vol. 14 (2013) Nr. 8, pp. 733 - 740Online Full Text: dx.doi.org/
-
A Landscape of Driver Mutations in MelanomaIn: Cell Vol. 150 (2012) Nr. 2, pp. 251 - 263Online Full Text: dx.doi.org/
-
Advances and perspectives in immunotherapy of melanomaIn: Annals of Oncology Vol. 23 (2012) Nr. Suppl. 10, pp. x104 - x108Online Full Text: dx.doi.org/ Online Full Text
-
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB) : A multicentre, open-label, phase 2 trialIn: The Lancet Oncology Vol. 13 (2012) Nr. 11, pp. 1087 - 1095Online Full Text: dx.doi.org/
-
Melanoma genome sequencing reveals frequent PREX2 mutationsIn: Nature Vol. 485 (2012) Nr. 7399, pp. 502 - 506Online Full Text: dx.doi.org/
-
Sorafenib and pegylated interferon-α2b in advanced metastatic melanoma : A multicenter phase II DeCOG trialIn: Annals of Oncology Vol. 22 (2011) Nr. 7, pp. 1667 - 1674Online Full Text: dx.doi.org/
-
Ipilimumab monotherapy in patients with pretreated advanced melanoma : a randomised, double-blind, multicentre, phase 2, dose-ranging studyIn: The Lancet Oncology Vol. 11 (2010) Nr. 2, pp. 155 - 164Online Full Text: dx.doi.org/